🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Penpulimab approved for non-keratinizing NPC (follows recent approval of toripalimab for similar indication) Now i do not have much else to say about this besides the fact that as a Hungarian i MUST highlight that “puli” stands for the smartest/cutest magyar (Hungarian) dog

Beyond thrilled to have presented my first poster at #ASCO25. Immensely grateful to my mentors Dr Tefferi and Naseema Gangat for their guidance and support! ASCO Mayo Clinic Comprehensive Cancer Center

🗣️Prostate Oral Abstract #ASCO25 👉Abst5000: Dr #TedDeWeese presenting #CAN2409+prodrug +EBRT +/-ADT in Int/High Risk PCa #CAN2409 is a replication-defective adenovirus 🦠HSV-tk gene 🧬 w/ prodrug promoting immunogenic cell death ☠️ and immunize 💉against tumor antigens for

NIVOPOSTOP Trial Demonstrates DFS Benefit of Adjuvant Nivolumab in High-Risk HNSCC Following Chemoradiotherapy dailynews.ascopubs.org/do/nivopostop-…

Very proud of you, Laura, and The Marsden team #hncsm #headneck ⁦The Royal Marsden NHS Foundation Trust⁩ thetimes.com/uk/healthcare/…

After Keynote689, some questions/brain storming: 💢Benefit even for PDL1 CPS/TPS negative pts? Only 16 pts per arm 🩹OS and local relapse/PD% in future IAs 💡Level of impact from neoadj part? 🩻 Benefit stratification depending mPR/neoORR? 🖋️Description of ~12% cases not

New Systematic Review (Cancer Cell, June 2025) 💉 Low-dose PD-(L)1 for Cancer Immunotherapy Largest Review till date 📊 32 studies | 2,055 pts ✅ >65% showed ≥80% cost savings 🧬 Responses seen in HL, lung, RCC 🏥 53% studies from LMICs 🧠 Bottom line: 💸 Promising for access.

Looking back on #ESMORareCancers25 💙 We proudly shared two UKSGCRWG-led studies on salivary gland cancer, highlighting the urgent need for research and collaboration in this rare disease space. #SGCUK #RareCancers #CancerResearch #Oncology

Our new paper on low-dose anti-PD-(L)1 is now published in European Journal of Cancer! Incredible experience working alongside all the co-authors on such an important topic Dario Trapani Dr Amol Akhade Dr Amol Akhade 👇 doi.org/10.1016/j.ejca…

#BREAKING The FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable locally advanced #HeadandNeck cancer in 20+ years. Approval based on the pivotal KEYNOTE-689 trial led by Ravi Uppaluri, MDPhD of the Dana-Farber Brigham Cancer Center.

💥Neoadjuvant pembrolizumab has received the approval for PDL1 CPS≥1 head&neck SCC by FDA! 🛎️This will require quick CPS testings Not surprising seen this restricion for negative CPS, having only 16 patients in each arm of KEYNOTE689 without presenting their specific outcomes

Los científicos advierten de los riesgos en el procedimiento que se ha hecho Orlando Bloom recientemente y que no hay evidencia de que este sistema funcione, por lo que apelan a centrarse en la prevención: reducir al máximo la exposición a microplásticos elpais.com/salud-y-bienes…

🚨Neo and adjuvant pembrolizumab for patients with resectable head and neck squamous cell carcinoma (KEYNOTE689) is now published in NEJM 💥Great step forward in the field Awaiting OS in next interim analyses Will NIVOPOSTOP be approved by FDA as well? U.S. FDA What would be

🧵 ¿Apixabán🆚 rivaroxabán para ETEV? 📊 Nuevos datos comparativos sobre seguridad y eficacia. Lana Castellucci presentando el ensayo 🐍COBBRA - el 1er ECA que compara apixabán🆚 rivaroxabán durante 3 meses. Los resultados son claros… te lo cuento en este hilo 👇 #ISTH2025

Happy to share the final results of the 🇪🇸 & 🇫🇷 ph2 trial of intratumoral BO-112 + pembro for patients with anti PD-1 resistant #melanoma. 25% ORR and 54% patients alive at 2 years. 16 years of basic and clinical research behind. Some context here 👇🧵 ascopubs.org/doi/10.1200/JC…

🔥 We got the cover of the June issue of Nature Cancer with our paper! 🌟 A huge honor and a recognition of the team’s hard work. 🔗 lnkd.in/dd6dE7A4 📄 See lnkd.in/dfd3hfi2

💥New combined updated long-term analysis from RTOG 9501 + EORTC 22931 published this week in Annals of Oncology ESMO - Eur. Oncology Median follow-up 7 years 💢Survival benefit from postop CRT may be not limited to patients with HNSCC positive margins or ENE (highlighted in figure) ⁉️Should

For Head and Neck Cancer Day, we’re highlighting the top #HNC oncologists with most views on 𝕏 in 2025. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData

On Head and Neck Cancer Day, we’re sharing key anticipated milestones expected in 2025. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights